EGRX News and Press, Eagle Pharmaceuticals Inc. From 08/20/21

The company is hiring Alvarez & Marsal, which specializes in bankruptcy restructuring. The move is somewhat surprising from a timing perspective. New York opioid and Vasostrict trials are still ongoing. For further details see: Endo International: Hires Restructuring...

Image source: The Motley Fool. Eagle Pharmaceuticals, inc (NASDAQ: EGRX) Q2 2021 Earnings Call Aug 9, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Eagle Pharmaceuticals, inc (EGRX) Q2 2021 Earnings Call Transcrip...

Eagle Pharmaceuticals, Inc. (EGRX) Q2 2021 Earnings Conference Call August 09, 2021, 08:30 AM ET Company Participants Lisa Wilson – Investor Relations Scott Tariff – Chief Executive Officer Judith Ng-Cashin – Chief Medical Officer Brian Cahill – Chief Financial Off...

Q2 2021 net income was $0.28 per basic and $0.27 per diluted share and adjusted non-GAAP net income was $0.95 per basic and $0.93 per diluted share Announced licensing agreement for U.S. commercial rights to Landiolol, a beta-1 adrenergic blocker and a leading hospital emergency use...

-- Eagle poised to facilitate regulatory pathway for approval in the U.S. based on existing data from Japanese and European studies, with no additional clinical work expected – -- Anticipates filing new drug application (“NDA”) in Q1 2022, with expected ten-mont...

Company settled with the eastern TN counties for $35mm but do the economics make any sense? NY litigation is ongoing with plaintiffs seeking default liability judgment on the same grounds as TN. Vasostrict trial with Eagle Pharmaceuticals is ongoing. >25% of EBITDA at risk. ...

Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 second quarter financial results on Monday, August 9, 2021, before the market opens. Scott Tarriff, Chief Executive Officer, and B...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

-- Assigned GDUFA date of December 15, 2021, and expects commercial launch prior to year-end -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug and Administration (“FDA”) ...

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has responded to the Complete Response Letter (“CRL”) for its Abbreviated New Drug Application (“ANDA”) for vasopressin received from the...